TSX News -
ProMIS Neurosciences Outlines Best-in-class Approach to Amyloid-beta-targeting Drug Candidates for Alzheimer’s Disease
TORONTO and CAMBRIDGE, Mass., Nov. 07, 2019 (GLOBE NEWSWIRE) — ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company […]